|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, September 30, 2014 ) Dallas, TX -- Researcher’s clinical trial report, “Hyperemia Global Clinical Trials Review, H2, 2014″ provides data on the Hyperemia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hyperemia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hyperemia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Researcher’s team of industry experts.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Purchase a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=214291 .
Scope
• Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
• Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
• Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
• Understand the dynamics of a particular indication in a condensed manner
• Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
• Obtain discontinued trial listing for trials across the globe
• Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Inquire for Discount @ http://www.rnrmarketresearch.com/contacts/discount?rname=214291 . (Report Price: Single User License – US$ 2500 and Corporate User License – US$ 7500)
Table of Contents
Table of Contents 2
List of Tables3
List of Figures 4
Introduction 5
Hyperemia 5
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Countries Contributing to Clinical Trials in Europe 10
Top Countries Contributing to Clinical Trials in North America 11
Clinical Trials by G7 Countries: Proportion of Hyperemia to Cardiovascular Clinical Trials 12
Clinical Trials by Phase in G7 Countries 13
Clinical Trials in G7 Countries by Trial Status 14
Clinical Trials by Phase 15
In Progress Trials by Phase 16
Clinical Trials by Trial Status 17
Clinical Trials by End Point Status 18
Subjects Recruited Over a Period of Time 19
Clinical Trials by Sponsor Type 20
Prominent Sponsors 21
Top Companies Participating in Hyperemia Therapeutics Clinical Trials 22
Prominent Drugs 23
Clinical Trial Profiles 24
Clinical Trial Overview of Top Companies 24
Valeant Pharmaceuticals International, Inc. 24
Clinical Trial Overview of Valeant Pharmaceuticals International, Inc. 24
Riemser Pharma GmbH 25
Clinical Trial Overview of Riemser Pharma GmbH 25
Dr. Reddy's Laboratories Limited 26
Clinical Trial Overview of Dr. Reddy's Laboratories Limited 26
Clinical Trial Overview of Top Institutes / Government 27
The University of Tokyo 27
Clinical Trial Overview of The University of Tokyo 27
University Hospital, Grenoble 28
Clinical Trial Overview of University Hospital, Grenoble 28
Institut Curie 29
Clinical Trial Overview of Institut Curie 29
Radboud University 30
Clinical Trial Overview of Radboud University 30
About Us:
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.
RnR Market Research
Ritesh Tiwari
+ 1-888-391-5441
sales@rnrmarketresearch.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
